Furthermore, significantly lower levels of antitumorigenic cytokines TNF-α and IFN-γ (p < 0.05, Figures 4(h) and 4(i)) and significantly higher levels of TGF-β and IL-10 (p < 0.001, Figures 2(j) and 2(k)) were noticed in the plasma samples of B16F10+MSC14d-treated mice, indicating that MSCs, injected during the progressive stage of melanoma development, attenuated antitumor immunity by increasing production of immunosuppressive cytokines in tumor-bearing animals. The gene discussed is TNF; the disease is melanoma.